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IVT-AFL 2q8 versus ranibizumab 0.5q4, and an indirect comparison of IVT-AFL 
2q8 with ranibizumab 0.5PRN data. A de novo health economic model combined 
these clinical inputs with Dutch-specific costs associated with treatment, moni-
toring, and indirect caregiving, and utility inputs relevant to a Dutch popula-
tion. Total quality-adjusted life-years (QALYs) and costs were calculated over a 
15-year horizon. Uncertainty around the outcomes was tested through sensitivity 
analyses. Results: Compared with ranibizumab 0.5q4, a 2-year treatment IVT-
AFL is associated with a significantly lower cost of € 7337 (95% CI: € 7248–€ 7435) 
over a 15-year horizon. There is no significant difference in QALYs (–0.0027 [95% 
CI: –0.0057 to 0.0001]). IVT-AFL 2q8 also has significantly lower total costs than 
ranibizumab 0.5PRN (€ 2450 [95% CI: € 2349–€ 2549]), with a nonsignificant gain of 
0.0007 QALYS (95% CI: –0.0023 to 0.0036). Probabilistic analyses show that, due to 
its lower costs, IVT-AFL 2q8 treatment had an estimated > 99% probability of being 
cost-effective compared with both of the ranibizumab treatment strategies at a 
willingness-to-pay threshold of € 20,000 per QALY, the proposed informal Dutch 
threshold. The univariate analyses did not alter the conclusions. ConClusions: 
The analysis showed that IVT-AFL 2q8 treatment is associated with cost savings 
versus ranibizumab 0.5q4 or 0.5PRN. There is no significant difference in total 
QALYs between the treatments. Due to lower overall costs, IVT-AFL is a cost-
effective treatment option for wAMD patients in the Netherlands.
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objeCtives: A cost-utility model was developed to assess the impact of plac-
ing apremilast, a new oral treatment, before biologics in patients with moderate 
to severe plaque psoriasis who have failed to respond to, have a contraindica-
tion to, or are intolerant to other systemic treatments from a Spain payer per-
spective. Methods: A 20-year Markov model with monthly cycle duration was 
developed. Treatment strategies consisted of apremilast prior to a biologic drug 
sequence compared with a biologic-only sequence. Sequential biologics, based 
on Spanish clinical practice, were adalimumab, ustekinumab, etanercept, and 
infliximab for both strategies. Patients who failed infliximab were assumed to 
receive best supportive care. A ≥ 75% reduction in Psoriasis Area and Severity 
Index was used as the efficacy measure. Drug response rates were derived from 
a meta-analysis. All-cause overall mortality was considered. Resource consump-
tion was estimated by an expert panel; biologic doses were taken from sum-
maries of the product characteristics. According to the NHS perspective, total 
costs included drug acquisition (ex-factory price with mandatory deduction), 
administration (parenteral drugs), and monitoring costs. Unit costs (€ , 2014) were 
obtained from national databases. An annual discount rate of 3% was applied for 
costs and health benefits. Utilities were estimated from PASI response using a 
published regression equation. Sensitivity analyses were performed to test model 
robustness. Results: The administration of apremilast before a sequence of bio-
logic drugs was estimated to provide an additional 0.12 quality-adjusted life-years 
(QALYs): 12.37 QALYs vs. 12.25 QALYs with the biologic-only sequence. In the 
base-case assumptions, the apremilast sequence yielded lower total costs vs. the 
biologic-only sequence (€ 216,490 vs. € 224,359). ConClusions: The administration 
of apremilast before biologic drugs is a cost-saving strategy for the NHS in the 
treatment of patients with moderate to severe plaque psoriasis. This analysis was 
limited in that the model did not consider cost-effectiveness issues.
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objeCtives: To estimate the incremental cost-effectiveness ratio (ICER) of intra-
vitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic 
macular oedema (DMO) in Sweden. Methods: A Markov model was developed 
targeting patients with visual impairment due to DMO in Sweden, based on data 
from the VIVID/VISTA and RESTORE clinical trials. A one-eye model was used in 
base case and patients were followed according to visual acuity in their study eye 
with a time horizon of 15 years. Eight mutually exclusive, exhaustive health states 
were specified and defined in terms of ETDRS letters read. Benefits were measured 
with utility specified as a function of the visual acuity of both eyes in combination. 
The main outcome was incremental cost per additional quality-adjusted life-years 
(QALYs) evaluated from a societal perspective. Univariate and probabilistic sensitiv-
ity analyses (PSA), and scenario analyses were conducted. Results: Intravitreal 
aflibercept was shown to be cost-effective versus intravitreal ranibizumab with 
an ICER of 128,323 (€ 13,821) SEK/QALY gained. The higher total cost for intravitreal 
aflibercept compared to intravitreal ranibizumab predominantly reflected the drug 
and administration costs while intravitreal ranibizumab showed a higher cost for 
monitoring. The incremental cost and QALYs were estimated to 5,227 SEK (€ 563) 
and 0.041, respectively. Univariate sensitivity analyses showed that the ICER was 
sensitive to the number of treatments and the administration costs. PSA showed 
that with a willingness-to-pay threshold of 500,000 SEK/QALY intravitreal aflibercept 
was estimated to have 68% chance of being cost-effective compared with intravitreal 
ranibizumab. In a number of scenarios, intravitreal aflibercept was estimated to 
be cost-effective against intravitreal ranibizumab including: four different sets of 
utilities; adjustment of treatment duration and discount rates; different time hori-
zons and with and without indirect costs. ConClusions: In Sweden, intravitreal 
aflibercept may be a cost-effective option versus intravitreal ranibizumab for the 
treatment of DMO using 500 TSEK as threshold.
years. This sequence remained dominant or cost saving in all the deterministic 
sensitivity analyses, changing efficacy data, utility weights, or discount rates. 
Resultswere more sensitive to changes in the time horizon of the analysis. The 
probabilistic sensitivity analysis confirmed that the apremilast sequence was 
dominant or cost saving in a large majority of the simulations. ConClusions: 
This analysis suggests that the use of apremilast for treatment of moderate to 
severe psoriasis may represent a cost-saving option for the Italian NHS without 
any loss in patients’ quality of life.
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objeCtives: Choroidal neovascularization (CNV) is the most common vision-
threatening complication associated with pathologic myopia (PM), a progressive 
condition characterized by axial elongation and degenerative changes in the 
posterior segment of the eye. This study aimed to evaluate the cost effective-
ness of ranibizumab compared with verteporfin photodynamic therapy (vPDT) 
in patients with visual impairment due to myopic CNV in the Portuguese set-
ting. Methods: A Markov model was developed with health states defined by 
best-corrected visual acuity and a 3-month cycle length. The study has taken 
under National Health Service perspective and included societal perspective in 
an alternative scenario, considering a lifetime time horizon. The study was based 
on 2013 prices considering future costs and health outcomes to be discounted at 
5.0% per annum. The baseline characteristics considered were retrieved from the 
phase III RADIANCE study (Ranibizumab and vPDT Evaluation in Myopic CNV), and 
VIP study (Verteporfin in Photodynamic Therapy). Extensive sensitivity analyses 
tested the robustness of the model. Results: From NHS perspective, the lifetime 
cost of treating myopic CNV with ranibizumab was € 8,241.73 whereas vPDT was 
associated with a total cost of € 10,732.81. In the alternative scenario, from societal 
perspective those costs amount to € 8,815.22 and € 11.333,83, for ranibizumab and 
vPDT, respectively. Ranibizumab treatment produced higher cumulative quality-
adjusted life-years (QALYs; 8.95) than vPDT (8.70). Ranibizumab treatment was 
therefore dominant in both scenarios, with greater health gains and lower overall 
costs than vPDT. In the probabilistic sensitivity analysis, ranibizumab had a 100% 
probability of being cost effective compared with vPDT, at an informal willingness-
to-pay threshold of € 30.000/QALY. ConClusions: This cost effectiveness study 
indicates that the therapy with ranibizumab is dominant over vPDT for the treat-
ment of visual impairment due to CNV secondary to pathologic myopia from both 
NHS and society perspectives.
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objeCtives: The optimal treatment strategy for moderate to severe plaque 
psoriasis remains to be determined. In its absence, switching between various 
treatment options, especially biologics, is a common practice among prescribers. 
We assessed the cost-effectiveness of placing a new oral treatment, apremilast, 
before biologics for moderate to severe plaque psoriasis from a Scottish payer 
perspective. Methods: A 10-year Markov transition cohort model was developed 
comparing alternative treatment sequences: (1) apremilast followed by etanercept 
followed by adalimumab and (2) adalimumab followed by etanercept. Patients 
failing etanercept received best supportive care (BSC) as last line of treatment 
in both sequences. Response was defined as a 75% reduction in Psoriasis Area 
and Severity Index (PASI) score at the end of the trial periods (12-16 weeks). Non-
responders moved to the next treatment line. A 20% all-cause annual dropout 
rate was assumed for each treatment. Efficacy inputs were obtained from a net-
work meta-analysis. Unit costs were sourced from the British National Formulary, 
NHS reference costs, and other published sources. A 3.5% annual discount rate 
was applied to costs and quality-adjusted life-years (QALYs). Utility gains by PASI 
response were obtained from a published regression equation. Results: Placing 
apremilast before biologics was a dominant strategy. The apremilast arm pro-
vided an additional 0.74 years in which patients achieved a 75% reduction from 
baseline PASI score and an additional 0.09 QALYs (7.00 vs. 6.91 QALYs). Total time 
spent on biologics and in BSC was reduced by 0.47 and 1.01 years, respectively. 
Total costs were reduced by £3,206. Sensitivity analyses showed robust results. 
Similar Resultswere obtained when combinations of other biologics, including 
ustekinumab, were used in a 2- or 3-drug sequence. ConClusions: Placing 
apremilast before biologics is a dominant strategy in moderate to severe plaque 
psoriasis treatment.
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objeCtives: This study investigates the cost-effectiveness of 2 mg IVT-AFL every 
8 weeks (2q8), after 3 monthly starting doses, compared with 0.5 mg ranibizumab 
every 4 weeks (0.5q4) and a strategy of a 3-month 0.5q4 starting dose ranibizumab 
followed by 0.5 mg every 4–12 weeks as needed (0.5PRN) with 2-year treatment 
durations in Dutch wAMD patients. Methods: A cost-effectiveness analysis was 
conducted, utilising clinical data from head-to-head randomised clinical trials of 
